Biomol Ther.  2015 Jan;23(1):26-30. 10.4062/biomolther.2014.095.

Atractylochromene Is a Repressor of Wnt/beta-Catenin Signaling in Colon Cancer Cells

Affiliations
  • 1Research Center for Cell Fate Control and College of Pharmacy, Sookmyung Women's University, Seoul 140-742, Republic of Korea. ryuha@sookmyung.ac.kr
  • 2Department of Natural Medicine Resources, Semyung University, Jecheon 390-711, Republic of Korea.

Abstract

Wnt/beta-catenin signaling pathway was mutated in about 90% of the sporadic and hereditary colorectal cancers. The abnormally activated beta-catenin increases the cancer cell proliferation, differentiation and metastasis through increasing the expression of its oncogenic target genes. In this study, we identified an inhibitor of beta-catenin dependent Wnt pathway from rhizomes of Atractylodes macrocephala Koidzumi (Compositae). The active compound was purified by activity-guided purification and the structure was identified as 2,8-dimethyl-6-hydroxy-2-(4-methyl-3-pentenyl)-2H-chromene (atractylochromene, AC). AC suppressed beta-catenin/T-cell factor transcriptional activity of HEK-293 reporter cells when they were stimulated by Wnt3a or inhibitor of glycogen synthase kinase-3beta. AC down-regulated the nuclear level of beta-catenin through the suppression of galectin-3 mediated nuclear translocation of beta-catenin in SW-480 colon cancer cells. Furthermore, AC inhibits proliferation of colon cancer cell. Taken together, AC from A. macrocephala might be a potential chemotherapeutic agent for the prevention and treatment of human colon cancer.

Keyword

Atractylochromene; Wnt/beta-catenin; Colon cancer; Proliferation

MeSH Terms

Atractylodes
beta Catenin
Cell Proliferation
Colonic Neoplasms*
Colorectal Neoplasms
Galectin 3
Glycogen Synthase
Humans
Neoplasm Metastasis
Rhizome
Wnt Signaling Pathway
Galectin 3
Glycogen Synthase
beta Catenin
Full Text Links
  • BT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr